Asset Details
Do you wish to reserve the book?
Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
Do you wish to request the book?
Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
2006
Overview
This randomized, open-label trial compared two regimens for the initial treatment of human immunodeficiency virus (HIV) infection: tenofovir disoproxil fumarate and emtricitabine plus efavirenz or a fixed dose of zidovudine and lamivudine plus efavirenz. Through week 48, the first regimen was superior in terms of viral suppression, CD4-cell response, and adverse events leading to discontinuation of the medication. As this trial continues, it will be important to assess any differences in long-term toxic effects, especially with regard to lipoatrophy and hyperlipidemia.
For the initial treatment of HIV, a regimen of tenofovir and emtricitabine plus efavirenz was superior in terms of viral suppression, CD4-cell response, and adverse events through week 48.
Highly active antiretroviral therapy has fundamentally altered the course of human immunodeficiency virus (HIV) infection by making it possible to suppress the plasma viral load below the limit of detection and to increase the number of CD4 cells.
1
The cornerstone of durable suppression of HIV replication is maintenance of a potent and tolerable regimen to which the patient can adhere. Adherence is necessary to prevent the emergence and replication of drug-resistant strains of the virus.
2
Current guidelines for the management of HIV infection recommend the use of zidovudine or tenofovir disoproxil fumarate (DF) with lamivudine or emtricitabine as preferred nucleoside . . .
Publisher
Massachusetts Medical Society
Subject
/ Adenine - analogs & derivatives
/ Adult
/ Age
/ Aged
/ Anti-Retroviral Agents - adverse effects
/ Anti-Retroviral Agents - therapeutic use
/ Antibiotics. Antiinfectious agents. Antiparasitic agents
/ Antiretroviral Therapy, Highly Active - adverse effects
/ Biological and medical sciences
/ Deoxycytidine - adverse effects
/ Deoxycytidine - analogs & derivatives
/ Deoxycytidine - therapeutic use
/ Female
/ HIV
/ HIV Infections - drug therapy
/ Human immunodeficiency virus
/ Humans
/ Lamivudine - adverse effects
/ Lamivudine - therapeutic use
/ Male
/ Organophosphonates - adverse effects
/ Organophosphonates - therapeutic use
/ Pharmacology. Drug treatments
